By Debdeep Gupta | 05 Apr, 2024
US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%
Troubles rose again for Cipla Ltd as the US Food and Drug Administration slapped a form 483 with six inspectional observations on the drugmaker's manufacturing facility at Patalganga in Maharashtra. The continued regulatory stress for the company sent its shares down 1.5 percent in early trade on April 5.At 9.19 am, shares of Cipla were trading at Rs 1,450.95 apiece on the NSE.Cipla's Patalganga p...
Live Comments